zanidatamab

ESMO: Jazz HER2 bispecific posts 59% survival at 30 months in gastric cancer
Fierce Biotech
Mon, 09/16/24 - 09:50 am
Jazz Pharma
zanidatamab
gastroesophageal cancer
ESMO
ASCO: Jazz shares 'unprecedented' HER2 biliary tract cancer data ahead of FDA decision
Fierce Biotech
Sun, 06/2/24 - 02:48 pm
ASCO 2024
Jazz Pharmaceuticals
advanced biliary tract cancer
zanidatamab
Zymeworks halts plans for phase 2 ADC trial to mull 'evolving clinical landscape'
Fierce Biotech
Thu, 03/7/24 - 11:37 am
antibody-drug conjugate
clinical trials
Zymeworks
zanidatamab
Jazz hands Zymeworks a much-needed win for biliary tract cancer drug after peek at data
Fierce Biotech
Wed, 12/21/22 - 11:24 am
Zymeworks
Jazz Pharma
biliary tract cancer
zanidatamab